Progress of research on adjuvant radiotherapy for breast cancer
FAN Yuanyuan, LIAN Jianfeng
Department of Gynecology and Obstetrics, Hai’an Hospital of Traditional Chinese Medicine Affiliated to Yangzhou University Medical School, Hai'an 226600 China
范媛媛, 练剑锋. 乳腺癌辅助放疗研究进展[J]. 中国辐射卫生, 2023, 32(2): 193-197.
FAN Yuanyuan, LIAN Jianfeng. Progress of research on adjuvant radiotherapy for breast cancer. Chinese Journal of Radiological Health, 2023, 32(2): 193-197.
[1] Loibl S, Poortmans P, Morrow M, et al. Breast cancer[J]. Lancet, 2021, 397(10286): 1750-1769. DOI: 10.1016/S0140-6736(20)32381-3 [2] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660 [3] Arnold M, Morgan E, Rumgay H, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040[J]. Breast, 2022, 66: 15-23. DOI: 10.1016/j.breast.2022.08.010 [4] Li N, Deng YJ, Zhou LH, et al. Global burden of breast cancer and attributable risk factors in 195 countries and territories, from 1990 to 2017: results from the global burden of disease study 2017[J]. J Hematol Oncol, 2019, 12(1): 140. DOI: 10.1186/s13045-019-0828-0 [5] Yan J, Liu Z, Du SF, et al. Diagnosis and treatment of breast cancer in the precision medicine era[M]//Huang T. Precision medicine. New York: Springer, 2020: 53-61. DOI: 10.1007/978-1-0716-0904-0_5. [6] Bredin P, Walshe JM, Denduluri N. Systemic therapy for metastatic HER2-positive breast cancer[J]. Semin Oncol, 2020, 47(5): 259-269. DOI: 10.1053/j.seminoncol.2020.07.008 [7] Li Y, Zhang HJ, Merkher Y, et al. Recent advances in therapeutic strategies for triple-negative breast cancer[J]. J Hematol Oncol, 2022, 15(1): 121. DOI: 10.1186/s13045-022-01341-0 [8] Castaneda SA, Strasser J. Updates in the treatment of breast cancer with radiotherapy[J]. Surg Oncol Clin N Am, 2017, 26(3): 371-382. DOI: 10.1016/j.soc.2017.01.013 [9] Bai X, Liu Z, Zhang J, et al. Comparing of two dimensional and three dimensional fully convolutional networks for radiotherapy dose prediction in left-sided breast cancer[J]. Sci Prog, 2021, 104(3): 368504211038162. DOI: 10.1177/00368504211038162 [10] Boero IJ, Paravati AJ, Triplett DP, et al. Modern radiation therapy and cardiac outcomes in breast cancer[J]. Int J Radiat Oncol Biol Phys, 2016, 94(4): 700-708. DOI: 10.1016/j.ijrobp.2015.12.018 [11] Haussmann J, Corradini S, Nestle-Kraemling C, et al. Recent advances in radiotherapy of breast cancer[J]. Radiat Oncol, 2020, 15(1): 71. DOI: 10.1186/s13014-020-01501-x [12] Prat A, Pineda E, Adamo B, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer[J]. Breast, 2015, 24(S2): S26-S35. DOI: 10.1016/j.breast.2015.07.008 [13] Yin L, Duan JJ, Bian XW, et al. Triple-negative breast cancer molecular subtyping and treatment progress[J]. Breast Cancer Res, 2020, 22(1): 61. DOI: 10.1186/s13058-020-01296-5 [14] Mahtani R, Kittaneh M, Kalinsky K, et al. Advances in therapeutic approaches for triple-negative breast cancer[J]. Clin Breast Cancer, 2021, 21(5): 383-390. DOI: 10.1016/j.clbc.2020.12.011 [15] Won KA, Spruck C. Triple-negative breast cancer therapy: current and future perspectives (review)[J]. Int J Oncol, 2020, 57(6): 1245-1261. DOI: 10.3892/ijo.2020.5135 [16] Abdulkarim BS, Cuartero J, Hanson J, et al. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy[J]. J Clin Oncol, 2011, 29(21): 2852-2858. DOI: 10.1200/JCO.2010.33.4714 [17] Kyndi M, Sørensen FB, Knudsen H, et al. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish breast cancer cooperative group[J]. J Clin Oncol, 2008, 26(9): 1419-1426. DOI: 10.1200/JCO.2007.14.5565 [18] Miao K, Lei JH, Valecha MV, et al. NOTCH1 activation compensates BRCA1 deficiency and promotes triple-negative breast cancer formation[J]. Nat Commun, 2020, 11(1): 3256. DOI: 10.1038/s41467-020-16936-9 [19] Kazemzadeh A, Abedi I, Amouheidari A, et al. A radiobiological comparison of hypo-fractionation versus conventional fractionation for breast cancer 3D-conformal radiation therapy[J]. Rep Pract Oncol Radiother, 2021, 26(1): 86-92. DOI: 10.5603/RPOR.a2021.0015 [20] Whelan TJ, Pignol JP, Levine MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer[J]. N Engl J Med, 2010, 362(6): 513-520. DOI: 10.1056/NEJMoa0906260 [21] James ML, Lehman M, Hider PN, et al. Fraction size in radiation treatment for breast conservation in early breast cancer[J]. Cochrane Database Syst Rev, 2010, 11: CD003860. DOI: 10.1002/14651858.CD003860.pub3 [22] Haviland JS, Owen JR, Dewar JA, et al. The UK standardisation of breast radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials[J]. Lancet Oncol, 2013, 14(11): 1086-1094. DOI: 10.1016/S1470-2045(13)70386-3 [23] Smith BD, Bellon JR, Blitzblau R, et al. Radiation therapy for the whole breast: executive summary of an American society for radiation oncology (ASTRO) evidence-based guideline[J]. Pract Radiat Oncol, 2018, 8(3): 145-152. DOI: 10.1016/j.prro.2018.01.012 [24] Meattini I, Becherini C, Boersma L, et al. European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer[J]. Lancet Oncol, 2022, 23(1): e21-e31. DOI: 10.1016/S1470-2045(21)00539-8 [25] Hepel JT, Wazer DE. Update on partial breast irradiation[J]. Clin Breast Cancer, 2021, 21(2): 96-102. DOI: 10.1016/j.clbc.2020.04.003 [26] Recht A, McArthur H, Solin LJ, et al. Contemporary guidelines in whole-breast irradiation: an alternative perspective[J]. Int J Radiat Oncol Biol Phys, 2019, 104(3): 567-573. DOI: 10.1016/j.ijrobp.2018.10.014 [27] Manterola Burgaleta A, Asín Felipe G, Arias de la Vega F. Accelerated partial breast irradiation (APBI)[J]. Clin Transl Oncol, 2022, 24(8): 1657-1658. DOI: 10.1007/s12094-022-02821-y [28] Paine CH, Ash DV. Interstitial brachytherapy: past-present-future[J]. Int J Radiat Oncol Biol Phys, 1991, 21(6): 1479-1483. DOI: 10.1016/0360-3016(91)90322-u [29] Fentiman IS, Poole C, Tong D, et al. Inadequacy of iridium implant as sole radiation treatment for operable breast cancer[J]. Eur J Cancer, 1996, 32(4): 608-611. DOI: 10.1016/0959-8049(95)00639-7 [30] Strnad V, Ott OJ, Hildebrandt G, et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial[J]. Lancet, 2016, 387(10015): 229-238. DOI: 10.1016/S0140-6736(15)00471-7 [31] Keisch M. MammoSite®[J]. Expert Rev Med Devices, 2005, 2(4): 387-394. DOI: 10.1586/17434440.2.4.387 [32] Geary RL, Haddad T, Barry A, et al. A prospective feasibility study of MammoSite accelerated partial breast irradiation for early breast cancer[J]. Ir J Med Sci, 2020, 189(4): 1203-1208. DOI: 10.1007/s11845-020-02237-z [33] Niehoff P, Polgár C, Ostertag H, et al. Clinical experience with the MammoSite® radiation therapy system for brachytherapy of breast cancer: results from an international phase II trial[J]. Radiother Oncol, 2006, 79(3): 316-320. DOI: 10.1016/j.radonc.2006.05.010 [34] Shah C, Badiyan S, Ben Wilkinson J, et al. Treatment efficacy with accelerated partial breast irradiation (APBI): final analysis of the American society of breast surgeons MammoSite® breast brachytherapy registry trial[J]. Ann Surg Oncol, 2013, 20(10): 3279-3285. DOI: 10.1245/s10434-013-3158-4 [35] Kolářová I, Melichar B, Vaňásek J, et al. Special techniques of adjuvant breast carcinoma radiotherapy[J]. Cancers, 2022, 15(1): 298. DOI: 10.3390/cancers15010298 [36] Lemanski C, Azria D, Gourgou-Bourgade S, et al. Electrons for intraoperative radiotherapy in selected breast-cancer patients: late results of the Montpellier phase II trial[J]. Radiat Oncol, 2013, 8: 191. DOI: 10.1186/1748-717X-8-191 [37] Philippson C, Larsen S, Simon S, et al. Intraoperative electron radiotherapy in early invasive ductal breast cancer: 6-year median follow-up results of a prospective monocentric registry[J]. Breast Cancer Res, 2022, 24(1): 83. DOI: 10.1186/s13058-022-01582-4 [38] Coles CE, Griffin CL, Kirby AM, et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial[J]. Lancet, 2017, 390(10099): 1048-1060. DOI: 10.1016/S0140-6736(17)31145-5 [39] Vicini FA, Cecchini RS, White JR, et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial[J]. Lancet, 2019, 394(10215): 2155-2164. DOI: 10.1016/S0140-6736(19)32514-0 [40] Polgár C, Van Limbergen E, Pötter R, et al. Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009)[J]. Radiother Oncol, 2010, 94(3): 264-273. DOI: 10.1016/j.radonc.2010.01.014
